Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Accounts receivable | -1,624,000 | -1,425,000 | -1,349,000 | -961,000 | -739,000 |
| Other Working Capital | -893,000 | 300,000 | 3,757,000 | 2,021,000 | 361,000 |
| Other Operating Activity | 14,378,000 | 11,470,000 | 7,400,000 | 4,903,000 | 5,177,000 |
| Operating Cash Flow | $11,861,000 | $10,345,000 | $9,808,000 | $5,963,000 | $4,799,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,869,000 | -1,229,000 | -809,000 | -1,078,000 | -855,000 |
| Net Acquisitions | -3,927,000 | -1,179,000 | -1,061,000 | -9,433,000 | -830,000 |
| Purchase Of Investment | -96,000 | -136,000 | -159,000 | -184,000 | -119,000 |
| Sale Of Investment | 108,000 | 129,000 | 42,000 | 105,000 | 2,126,000 |
| Purchase Sale Intangibles | -2,539,000 | -2,126,000 | -1,033,000 | -522,000 | -694,000 |
| Other Investing Activity | 466,000 | 768,000 | 507,000 | 641,000 | 1,038,000 |
| Investing Cash Flow | $-7,980,000 | $-4,064,000 | $-2,960,000 | $-11,058,000 | $-285,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -31,000 | 161,000 | 74,000 | -276,000 | 288,000 |
| Debt Issued | 6,492,000 | 3,816,000 | 0 | 12,929,000 | 2,968,000 |
| Debt Repayment | -4,652,000 | -4,942,000 | -1,271,000 | -4,759,000 | -1,609,000 |
| Common Stock Issued | -43,000 | 33,000 | 29,000 | 29,000 | 30,000 |
| Dividend Paid | -4,629,000 | -4,481,000 | -4,364,000 | -3,856,000 | -3,572,000 |
| Other Financing Activity | -1,133,000 | -1,154,000 | -1,291,000 | -418,000 | -308,000 |
| Financing Cash Flow | $-3,996,000 | $-6,567,000 | $-6,823,000 | $3,649,000 | $-2,203,000 |
| Exchange Rate Effect | -93,000 | -60,000 | -80,000 | -62,000 | 12,000 |
| Beginning Cash Position | 5,637,000 | 5,983,000 | 6,038,000 | 7,546,000 | 5,223,000 |
| End Cash Position | 5,429,000 | 5,637,000 | 5,983,000 | 6,038,000 | 7,546,000 |
| Net Cash Flow | $-115,000 | $-286,000 | $25,000 | $-1,446,000 | $2,311,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 11,861,000 | 10,345,000 | 9,808,000 | 5,963,000 | 4,799,000 |
| Capital Expenditure | -4,586,000 | -3,778,000 | -2,571,000 | -2,200,000 | -2,606,000 |
| Free Cash Flow | 7,275,000 | 6,567,000 | 7,237,000 | 3,763,000 | 2,193,000 |